Treatment of Moderate to Severe Pruritus (Skin Itching) in Large Duct Primary Sclerosing Cholangitis
Moderate to severe pruritus is a clinically significant complication of large duct primary sclerosing cholangitis that can substantially impair quality of life. Management proceeds through a defined treatment sequence, with each stage addressing the failure of prior lines.
This protocol applies to patients with large duct sclerosing cholangitis who have moderate to severe pruritus (skin itching). Before escalating pharmacological treatment, relevant bile duct strictures should be excluded as a contributing or primary cause of progressive pruritus.
At the fourth-line stage, sertraline is an agent used for sclerosing cholangitis-associated itch, though its evidence base in this specific indication remains limited. The full sequence, individualisation criteria, and clinical decision points are detailed in the complete protocol.
References
DOI: 10.1016/j.jhep.2022.05.011
Pharmacological treatment of moderate to severe pruritus in sclerosing cholangitis with bezafibrate or rifampicin is recommended.
It is recommended to exclude relevant bile duct strictures in large duct sclerosing cholangitis as the cause of progressive pruritus.
For sertraline as fourth-line treatment, no sufficient data for sclerosing cholangitis-associated itch exist.
View source ↗